Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methyluracil→

Methyluracil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
626-48-2
Molecular formula
C5H6N2O2
Molecular weight
126.11 g/mol
Drug class
Pyrimidine derivativetissue-repair and haematopoietic-support agent
Mechanism of action
A pyrimidine derivative proposed to support nucleic-acid synthesis, cellular proliferation and tissue repair. It has been described as a stimulant of leucopoiesis and epithelial regeneration, although clinical evidence and mechanisms are limited.
Indications / reported uses
  • Topical use in selected wound-healing preparations and systemic use for selected haematopoietic or inflammatory conditions in countries where methyluracil is authorised; indications are product- and jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=methyluracil · https://www.ncbi.nlm.nih.gov/mesh/?term=methyluracil · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methyluracil Environmental Risk Assessment (ERA) (the Methyluracil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.